Loading stock data…
Pelthos Therapeutics Inc (PTHS)
$27.55-1.48 (-5.10%)
Market ClosedLast close Jun 29
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Pelthos Therapeutics Inc. in the Healthcare sector is trading at $27.55 with a market capitalization of $96M. Wall Street consensus targets $57.71 (7 analysts), implying a +109.5% move over the next 12 months. The stock is currently 49% below its 52-week high of $54.29, remaining 3.8% above its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +109.5% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $10.91M↑ | $9.39M↑ | $7.41M | $0 | $0 |
| Gross Profit | $5.59M↑ | $5.00M↑ | $2.43M | — | $0 |
| Operating Income | -$13.09M↓ | -$12.00M↑ | -$15.36M↓ | -$3.23M↓ | -$1.83M |
| Net Income | -$10.24M↑ | -$21.66M↓ | -$16.24M↓ | -$3.45M↓ | -$1.97M |
Peer Comparison
JNJUNHPFE
Fundamentals
Pelthos Therapeutics Inc., a bio-pharmaceutical company, develops and commercializes therapeutic products to help patients with unmet treatment burdens. The company offers ZELSUVMI for the treatment of molluscum contagiosum in adults and children 1 y...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$95.75M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-146.97%
Volume
Today's trading volume
26,842
Recent News
Pelthos Therapeutics Inc. Q1 2026 Earnings Call Summary
Moby summary of Pelthos Therapeutics Inc.'s Q1 2026 earnings call
Pelthos Therapeutics Inc (PTHS) Q1 2026 Earnings Call Highlights: Revenue Surge and Strategic ...
Pelthos Therapeutics Inc (PTHS) reports significant revenue growth and sales force expansion, despite facing a net loss and rising expenses in Q1 2026.
Pelthos Therapeutics Inc. (PTHS) Reports Q1 Loss, Beats Revenue Estimates
Pelthos Therapeutics Inc. (PTHS) delivered earnings and revenue surprises of +22.75% and +12.03%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Pelthos Therapeutics Maps Public-Market Path, ZELSUVMI Surge, Adds Xepi and Xeglyze in Roth Interview
Pelthos Therapeutics (NYSEAMERICAN:PTHS) executives detailed the company’s path to the public markets, early commercial traction for its lead product ZELSUVMI, and plans to add two additional pediatric-focused dermatology products during an investor interview hosted by Roth Capital Partners senior b
Pelthos Therapeutics Inc (PTHS) Q4 2025 Earnings Call Highlights: Prescription Surge and ...
Pelthos Therapeutics Inc (PTHS) reports a 129% increase in prescriptions and strategic acquisitions, bolstering its financial position and setting the stage for future growth.